Gilead Sciences: Overcoming COVID-19 in Early 2020: Keith's Story

Early in 2020, Keith Prowell was making the most of his retirement in New York and staying active with swimming and tai chi. But as reports of a new, unknown virus started spreading, he began not feeling well

"I started to feel like something was off and didn't know whether it was a cold or a flu or this new thing that was out there called COVID-19," recalls Keith.

Keith was instructed to isolate himself from his loved ones, including his wife and son. While in isolation, his breathing became labored. His cough grew worse and he was pale and weak. Concerned, Keith went to urgent care and was soon transferred to the hospital, where he tested positive for COVID-19.

"People were dying and the numbers were going up every day. I wondered if I was going to be a part of that statistic," he says.

While in the hospital, Keith was offered the opportunity to participate in a clinical trial for an antiviral therapy. He began receiving treatments right away and soon his breathing and speech improved.

Once he recovered, the experience left him inspired to spend more time with his family and to be fully present with those he encounters.

"When you come to a point that you feel like all of that would be lost overnight, you gain a deep appreciation of the little things that you go through every day," says Keith.

Originally published by Gilead Sciences

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com

SOURCE: Gilead Sciences



View source version on accesswire.com:
https://www.accesswire.com/747761/Gilead-Sciences-Overcoming-COVID-19-in-Early-2020-Keiths-Story

News Provided by ACCESSWIRE via QuoteMedia

GILD
The Conversation (0)
Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, is delighted to announce the appointment of Paul Carter as Non-Executive Director, effective 27 October 2025.Paul Carter is a highly... Keep Reading...
CHMP Adopts Positive Opinion Recommending Hepcludex®  for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus

CHMP Adopts Positive Opinion Recommending Hepcludex® for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus

-- If Granted by the European Commission, Hepcludex will Become the Only Approved Treatment for HDV in the EU -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive... Keep Reading...
Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts

Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts

The recent national conversation on hepatitis C (HCV) is an encouraging step towards viral hepatitis elimination in the U.S. With its long history of leadership in viral hepatitis, Gilead continues to support efforts that focus on HCV elimination. Gilead is proud that its medicines have treated... Keep Reading...
Gilead Sciences Announces First Quarter 2023 Financial Results

Gilead Sciences Announces First Quarter 2023 Financial Results

Product Sales Excluding Veklury Increased 15% Year-Over-Year to $5.7 billion Biktarvy Sales Increased 24% Year-Over-Year to $2.7 billion Oncology Sales Increased 59% Year-Over-Year to $670 million Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first... Keep Reading...
Gilead Sciences Releases Inaugural ESG Impact Report

Gilead Sciences Releases Inaugural ESG Impact Report

Gilead Sciences recently released its inaugural Environmental, Social and Governance (ESG) Impact Report. This is an evolution of our traditional Year in Review, and uses the ESG framework to highlight the successes and achievements of the prior yearThough the report itself is new, our... Keep Reading...

Latest Press Releases

Related News